Literature DB >> 31774462

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy.

Sahar Khan1, Alon Vaisman2,3, Susy S Hota2,3, Sabrina Bennett1, Suzanne Trudel1,3,4, Donna Reece1,3, Rodger E Tiedemann1,3,4.   

Abstract

Entities:  

Year:  2020        PMID： 31774462      PMCID： PMC6902180          DOI： 10.1001/jamaoncol.2019.5098

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

Review 1.  Treatment and disease-related complications in multiple myeloma: Implications for survivorship.

Authors:  Rajshekhar Chakraborty; Navneet S Majhail
Journal:  Am J Hematol       Date:  2020-03-13       Impact factor: 10.047

Review 2.  Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.

Authors:  Jakub Radocha; Niels W C J van de Donk; Katja Weisel
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

3.  Listeria monocytogenes Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma.

Authors:  Toshiyuki Ueno; Takanori Ohta; Hiroshi Imanaga; Megumi Nakazawa; Yoriko Sato; Yasuhiro Sugio; Yujiro Uchida; Yuju Ohno; Yasufumi Uehara
Journal:  Intern Med       Date:  2021-05-22       Impact factor: 1.271
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.